LOGIN  |  REGISTER
Terns Pharmaceuticals
Recursion

Elutia to Participate in Upcoming Investor Conferences

April 03, 2025 | Last Trade: US$2.39 0.30 14.35

SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences:

LD Micro 15th Annual Invitational – New York, NY
Format: Presentation and 1x1 Meetings
Presentation Date and Time: Thursday, April 10, 2025, 12:30 p.m. ET (9:30 a.m. PT)
Webcast: Click Here

Planet Microcap Showcase – Las Vegas, NV
Format: Presentation and 1x1 Meetings
Presentation Date and Time: Wednesday, April 23, 2025, 4:00 p.m. ET (1:00 p.m. PT)
Webcast: Click Here

Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro or Planet Microcap representative or email This email address is being protected from spambots. You need JavaScript enabled to view it..

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Matt Steinberg
FINN Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.

This press release was published by a CLEAR® Verified individual.

C4 Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page